Zobrazeno 1 - 5
of 5
pro vyhledávání: '"enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-tirosina cinasas [COMPUESTOS QUÍMICOS Y DROGAS]"'
Autor:
Natalia Estrada, Lurdes Zamora, Francisca Ferrer-Marín, Laura Palomo, Olga García, Patricia Vélez, Iris De la Fuente, Miguel Sagüés, Marta Cabezón, Montserrat Cortés, Rolando Omar Vallansot, María Alicia Senín-Magán, Concepción Boqué, Blanca Xicoy
Publikováno v:
Scientia
Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 6217
Journal of Clinical Medicine; Volume 11; Issue 20; Pages: 6217
Chronic myeloid leukemia; Imatinib; Single-nucleotide polymorphisms Leucèmia mieloide crònica; Imatinib; Polimorfismes d'un sol nucleòtid Leucemia mieloide crónica; Imatinib; Polimorfismos de un sólo nucleótido Imatinib is the most common first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4df9b0a89f39aecaece2124d53b508dd
http://hdl.handle.net/11351/8974
http://hdl.handle.net/11351/8974
Autor:
Montalban, Xavier, Wallace, Daniel, Genovese, Mark C., Tomic, Davorka Lucia, Parsons-Rich, Dana, Le Bolay, Claire, Kao, Amy H., Guehring, Hans, Universitat Autònoma de Barcelona
Publikováno v:
Scientia
ObjectiveAnalyse the integrated safety profile of evobrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), using pooled data from multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) trials.MethodsPhase II, ran
Autor:
Juan A, Fernández-Hernández, Sonia, Cantín-Blázquez, Elena, García-Somacarrera, Evaristo, Varo-Pérez, José A, González-López, José M, Asencio-Pascual, Marta, Mendiola, César, Serrano, Eduardo, García-Granero, Vicente, Artigas-Raventós
Publikováno v:
Scientia
Tumores del estroma gastrointestinal; Inhibidores de la tirosina cinasa; Laparoscopia Gastrointestinal stromal tumors; Tyrosine kinase inhibitors; Laparoscopy Tumors de l'estroma gastrointestinal; Inhibidors de la tirosina cinasa; Laparoscòpia Los t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db022dfbf5739ba878838603bc499034
https://hdl.handle.net/11351/9683
https://hdl.handle.net/11351/9683
Autor:
Tanios Bekaii-Saab, Hiroya Taniguchi, Jean-Baptiste Bachet, Teresa Macarulla, Rui Hua Xu, Shan Zeng, Fotios Loupakis, Satoshi Yuki, Lorenzo Antonuzzo, Feng Che Kuan, Thomas Winder, Filippo Pietrantonio
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Scientia
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, SAGE Journals, 2020, 12, pp.1758835920956862. ⟨10.1177/1758835920956862⟩
Scientia
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, SAGE Journals, 2020, 12, pp.1758835920956862. ⟨10.1177/1758835920956862⟩
Esdeveniments adversos; Càncer colorectal metastàtic; Regorafenib Eventos adversos; Cáncer colorrectal metastásico; Regorafenib Adverse events; Metastatic colorectal cancer; Regorafenib Over the past 20 years, management of patients with metastat
Autor:
Pablo Maroto, Camillo Porta, Jaume Capdevila, Andrea B. Apolo, Santiago Viteri, Cristina Rodriguez-Antona, Lidia Martin, Daniel Castellano
Publikováno v:
Scientia
Cabozantinib; Hepatocellular carcinoma; Solid tumor Cabozantinib; Carcinoma hepatocel·lular; Tumor sòlid Cabozantinib; Carcinoma hepatocelular; Tumor sólido Background: Cabozantinib is approved, in various settings, for the treatment of renal cell